Navigation Links
Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
Date:5/13/2009

SOUTH SAN FRANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the Leerink Swann Oncology Roundtable Conference on Wednesday, May 20, at 2:00 p.m. Eastern Time in New York.

Dr. McMahon's corporate presentation will include a discussion about the clinical development program for the Company's lead product candidate, picoplatin. In addition, Dr. McMahon will participate in an expert panel discussion on the same day at 8:10 a.m. Eastern Time entitled "New Developments in Solid Tumors, Focusing on GU and GI Cancers."

A live audio webcast of the corporate overview will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
2. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
4. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
5. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
6. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
7. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017  Kingfisher Talent, ... search and leadership development, and Virdis Group, global executive search ... exclusive alliance that enables clients to leverage the expertise and ... "For our clients here in the Boston ... diverse population of leadership talent throughout the US, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is pleased to ... and scientific instruments. This year’s symposium, organized by the Pittcon 2018 program chair, ... Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high throughput IMS-MS ...
(Date:8/15/2017)... Linda, Ca (PRWEB) , ... August 15, 2017 ... ... coffee production and is threatened by various biotic and abiotic factors. During this ... complex evolutionary history of coffee, as well as gain a better understanding of ...
(Date:8/14/2017)... ... 14, 2017 , ... The Conference Forum has confirmed the one-day ... on September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning ... and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
Breaking Biology News(10 mins):